A cancer drug that Eli Lilly was positioning as a challenger to similar drugs from rivals Pfizer and Novartis has failed a late-stage clinical trial in lung cancer. Indianapolis-based Lilly (NYSE: LLY) said Tuesday that its drug, abemaciclib (Verzenio), did not meet the Phase 3 study’s main goal of improving overall survival in patients who […]
Original Article: Eli Lilly Drug Fails in Lung Cancer, Stalling Oncology Strategy
NEXT ARTICLE